MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Agreement in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:
MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement in a Year will not exceed, in the aggregate, the maximum credit value set forth below:
MAXIMUM CREDIT VALUE. Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Agreement in a Year will not exceed[*]. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: 1 [***] [***] [***] [***] 2 [***] [***] [***] [***] 3 [***] [***] [***] [***] 4 [***] [***] [***] [***] 5 [***] [***] [***] [***] THIS FIRST AMENDMENT TO RISPERIDONE PRODUCT AGREEMENT (this “Amendment”), effective as of January 1, 2019 (“Amendment Effective Date”), is made between Indivior UK Limited (“Indivior”) and Patheon Manufacturing Services LLC (“Patheon”). Indivior and Patheon may be referred to herein individually as a “Party” or collectively, as “Parties.”
MAXIMUM CREDIT VALUE. Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for the Product in a Year will not exceed, in the aggregate for purposes of this Product Agreement, the maximum credit value set forth below: [ ]% of revenues per Year to Patheon under this Product Agreement, up to a maximum of $[ ] in the aggregate per Year. TO: SALIX PHARMACEUTICALS, INC FROM: PATHEON PHARMACEUTICALS INC. [or applicable Patheon entity] RE: Active Materials quarterly inventory report under Section 2.2(a) of the Master Manufacturing Services Agreement dated May 21, 2013 (the “Agreement”) Active Materials on hand at beginning of quarter: kg (A) Active Materials on hand at end of quarter: kg (B) Quantity Received during quarter: kg (C) Quantity Dispensed(1) during quarter: (A + C - B) kg Quantity Converted during quarter: (total Active Materials in Products produced and not rejected, recalled or returned) kg Capitalized terms used in this report have the meanings given to the terms in the Agreement. PATHEON PHARMACEUTICALS INC. DATE: [or applicable Patheon entity] Per: Name: Title:
MAXIMUM CREDIT VALUE. Supplier’s liability for Supernus Supplied Materials calculated in accordance with Section 5 of the Agreement for the Product in a calendar year will not exceed, in the aggregate **.
MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 will be resolved in the following manner:
MAXIMUM CREDIT VALUE. Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Agreement for any Product in a Year shall not exceed, in the aggregate, the maximum credit value set forth below: Zolpidem Tartrate Tablets (a) [***]; (b) [***], (c) [***]. [***] Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from this exhibit and have been filed separately with the Securities and Exchange Commission.
MAXIMUM CREDIT VALUE. Patheon’s liability for Active Materials in accordance with Section 10.2 of the Agreement will not exceed in any one year, in the aggregate, the maximum credit value set forth below: Angiomax® / Angiox® [**]% of the annual conversion costs invoiced by Patheon and paid by MDCO for the manufacture of Product. during the Year in which the API’s loss occurs. Final calculation of the Maximum Credit Value will be made following the end of the applicable Year.
MAXIMUM CREDIT VALUE. Patheon’s liability for Active Material calculated in accordance with Section 2.2 in a Year will not exceed, in the aggregate, the maximum credit value set forth below: BC-3781 [**]% of revenues (being payments of the Price) per Year received by Patheon under this Agreement.
